FDA Approves ZILBRYSQ — UCB, Inc.

UCB, Inc. announced on Thursday that the FDA granted accelerated approval to its novel antiphospholipid syndrome drug ZILBRYSQ (zilucoplan), signaling a strategic entry into the underserved autoimmune market while positioning the manufacturer to challenge established competitors in the rapidly evolving complement inhibitor landscape. The approval of the subcutaneous therapy, effectively competing with companies like Alexion Pharmaceuticals, may drive significant revenue growth and influence market dynamics as UCB seeks to leverage its strong foothold in neurology to expand its pharmaceutical portfolio.